MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

The latest financial statement is for the quarter ending 2025-09-30.

Cash Flow Overview

Free Cash flow
-$34,959K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Depreciation
-1,036
Net loss
-40,666 -76,913
Depreciation
523 1,036
Stock-based compensation
8,085 16,792
Accretion of discount on marketable securities, net
2,056 4,126
Amortization of right-of-use asset
47 85
Prepaid expenses and other assets
1,298 3,950
Accounts payable
-2,132 2,707
Accrued compensation
2,362 -4,420
Accrued other expenses and other liabilities
548 -1,293
Lease liability
-189 -366
Net cash used in operating activities
-34,776 -70,448
Maturities of marketable securities
-229,118
Purchases of marketable securities
66,999 385,942
Sales of marketable securities
51,452 38,650
Maturities of marketable securities
319,120 -
Purchases of property and equipment
183 94
Net cash used in investing activities
35,716 -118,268
Proceeds from issuance of common stock, net of offering costs
0 187,362
Exercise of stock options
1,659 2,494
Proceeds from employee stock purchase plan
0 598
Net cash provided by financing activities
1,659 190,454
Net change in cash and cash equivalents
2,599 1,738
Cash and cash equivalents at beginning of period
41,666 -
Cash and cash equivalents at end of period
46,003 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

Edgewise Therapeutics, Inc. (EWTX)

Edgewise Therapeutics, Inc. (EWTX)